• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Malley Thomas

    3/20/26 9:00:03 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KURA alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Malley Thomas

    (Last)(First)(Middle)
    C/O KURA ONCOLOGY, INC.
    4930 DIRECTORS PLACE, SUITE 500

    (Street)
    SAN DIEGO CALIFORNIA 92121

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Kura Oncology, Inc. [ KURA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/18/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock03/18/2026M(1)10,000A$3.1210,000D
    Common Stock139,557IBy Mossrock Capital, LLC(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (Right to Buy)$3.1203/18/2026M(1)10,000 (3)05/11/2026Common Stock10,000$00D
    Explanation of Responses:
    1. Represents stock options exercised.
    2. Mr. Malley serves as President of Mossrock Capital, LLC and has sole voting and investment power over these shares.
    3. This option is fully vested.
    /s/ Teresa Bair, Attorney-in-fact for Thomas Malley03/19/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $KURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KURA

    DatePrice TargetRatingAnalyst
    4/14/2026$23.00Buy
    Lake Street
    9/4/2025Neutral
    Guggenheim
    2/6/2025Buy → Neutral
    BTIG Research
    10/24/2024$27.00Buy
    UBS
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    12/22/2023$26.00Buy
    Mizuho
    8/11/2023$31.00Buy
    BofA Securities
    7/27/2023$10.50Sector Perform
    Scotiabank
    More analyst ratings

    $KURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

    – Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors – – New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings – – First planned platform combination, darlifarnib + da

    6/3/26 6:53:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

    – 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months – – Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure – – Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed – SAN DIEGO and TOKYO, June 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced the publication in Blood of updated resul

    6/2/26 8:32:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

    – Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data fro

    5/26/26 6:02:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Powl Brian T. sold $110,000 worth of shares (10,000 units at $11.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 173,614 units (SEC Form 4)

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    5/22/26 4:05:07 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Bair Teresa Brophy sold $21,160 worth of shares (2,256 units at $9.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.98% to 226,931 units (SEC Form 4)

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    5/20/26 4:05:18 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Powl Brian T. sold $3,122 worth of shares (339 units at $9.21) as part of a pre-agreed trading plan, decreasing direct ownership by 0.18% to 183,614 units (SEC Form 4)

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    5/20/26 4:05:22 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Kura Oncology Inc.

    DEFA14A - Kura Oncology, Inc. (0001422143) (Filer)

    5/26/26 4:38:11 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Kura Oncology Inc.

    SCHEDULE 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    5/15/26 11:26:19 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Kura Oncology Inc.

    10-Q - Kura Oncology, Inc. (0001422143) (Filer)

    5/12/26 4:15:38 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Kura Oncology with a new price target

    Lake Street initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $23.00

    4/14/26 8:04:53 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Kura Oncology

    Guggenheim initiated coverage of Kura Oncology with a rating of Neutral

    9/4/25 9:01:23 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology downgraded by BTIG Research

    BTIG Research downgraded Kura Oncology from Buy to Neutral

    2/6/25 7:53:07 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Wilson Troy Edward bought $410,145 worth of shares (50,000 units at $8.20), increasing direct ownership by 98% to 100,968 units (SEC Form 4)

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    9/9/25 4:28:40 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Financials

    Live finance-specific insights

    View All

    Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

    – Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors – – New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings – – First planned platform combination, darlifarnib + da

    6/3/26 6:53:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

    – Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data fro

    5/26/26 6:02:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports First Quarter 2026 Financial Results

    – $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase

    5/12/26 4:02:00 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $KURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kura Oncology Inc.

    SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

    12/5/24 6:55:37 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:31:29 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:32:22 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care